344 related articles for article (PubMed ID: 37497748)
21. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.
Agarwal N; Azad A; Shore ND; Carles J; Fay AP; Dunshee C; Karsh LI; Paccagnella ML; Santo ND; Elmeliegy M; Lin X; Czibere A; Fizazi K
Future Oncol; 2022 Feb; 18(4):425-436. PubMed ID: 35080190
[TBL] [Abstract][Full Text] [Related]
22. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
23. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
Agarwal N; Zhang T; Efstathiou E; Sayegh N; Engelsberg A; Saad F; Fizazi K
Eur J Cancer; 2023 Oct; 192():113249. PubMed ID: 37672815
[TBL] [Abstract][Full Text] [Related]
24. Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors.
Roy S; Saad F
Curr Opin Support Palliat Care; 2022 Dec; 16(4):223-229. PubMed ID: 36349381
[TBL] [Abstract][Full Text] [Related]
25. Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
[TBL] [Abstract][Full Text] [Related]
26. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
[TBL] [Abstract][Full Text] [Related]
27. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
28. Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.
Akbıyık I; Ürün Y
Future Oncol; 2023 Dec; 19(39):2585-2591. PubMed ID: 38073492
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer.
Chen X; Pan Y; Wang Q; Ren C; Li M; Hao X; Xie L; Liu X
Front Endocrinol (Lausanne); 2023; 14():1225033. PubMed ID: 38027160
[TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of first-line systemic treatments for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Ai J; Jian L; Wen X; Huo X; Yang X; Jiang J; Zhang T
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38750344
[TBL] [Abstract][Full Text] [Related]
31. Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials.
Yanagisawa T; Kawada T; Rajwa P; Kimura T; Shariat SF
Curr Opin Urol; 2023 May; 33(3):219-229. PubMed ID: 36692012
[TBL] [Abstract][Full Text] [Related]
32. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
Loehr A; Hussain A; Patnaik A; Bryce AH; Castellano D; Font A; Shapiro J; Zhang J; Sautois B; Vogelzang NJ; Chatta G; Courtney K; Harzstark A; Ricci F; Despain D; Watkins S; King C; Nguyen M; Simmons AD; Chowdhury S; Abida W
Eur Urol; 2023 Mar; 83(3):200-209. PubMed ID: 36243543
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
[TBL] [Abstract][Full Text] [Related]
34. The emerging role of PARP inhibitors in prostate cancer.
Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
[TBL] [Abstract][Full Text] [Related]
35. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
[TBL] [Abstract][Full Text] [Related]
36. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer.
Agarwal N; Saad F; Azad AA; Mateo J; Matsubara N; Shore ND; Chakrabarti J; Chen HC; Lanzalone S; Niyazov A; Fizazi K
Future Oncol; 2024 Mar; 20(9):493-505. PubMed ID: 37882449
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
[TBL] [Abstract][Full Text] [Related]
38. Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients.
Giesen A; Baekelandt L; Devlies W; Devos G; Dumez H; Everaerts W; Claessens F; Joniau S
Front Oncol; 2023; 13():1265812. PubMed ID: 37810962
[TBL] [Abstract][Full Text] [Related]
39. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
Sciarra A; Frisenda M; Bevilacqua G; Gentilucci A; Cattarino S; Mariotti G; Del Giudice F; Di Pierro GB; Viscuso P; Casale P; Chung BI; Autorino R; Crivellaro S; Salciccia S
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614122
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Bieńkowski M; Tomasik B; Braun M; Jassem J
Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
